Dong-E-E-Jiao Stock
000423.SZSHZDong-E-E-Jiao Co.,Ltd., HealthcareISIN CNE0000006Y9
81Score 81 out of 100, Strong
Price and Trend
63 / 100
Price history
+7.4% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 2.8% above it.
Since June 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is 9.3% below its 52-week high. Largest decline in 20 years: 66% (June 2017 to March 2020).
Chart figures for advanced users
- SMA 50$7.20
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.61
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$6.52
- The lowest closing price of the last twelve months.
- Resistance$8.63
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Dong-E-E-Jiao Co.,Ltd. belongs to the Drug Manufacturers (Specialty & Generic) industry (China) and, with a market value of $5.01B, is number 43 of 75 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $996.55M (up 12.2% year on year) and earnings of $260.81M (up 11.7%).
- For fiscal 2026, analysts expect on average revenue of $1.08B (up 7.9%) and adjusted earnings per share of $0.44 (up 9.7%).
Show more
- MEQIRI Score 81 out of 100 (Strong): rank 10 of 686 in Healthcare, median 53.
- The P/E is 18.5 (Drug Manufacturers (Specialty & Generic) median 30.3, own median of recent years 22.6).
- Our model puts fair value at $8.45, with the price 6% below it.
In Plain Words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per Share GrowingUp 109.5% a year since 2020.Growth 84
- High Return on CapitalReturn on invested capital 104.3% in fiscal 2025, Drug Manufacturers (Specialty & Generic) median 11.4%.Profitability 92
- More Cash than DebtCash $1.09B, financial debt $25.16M.Stability 95
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are stability and profitability.
Daily figure as of 20 Nov 2026
How the score is calculatedScore Overview
Score since yesterday from 80 to 81.
Fundamentals are strong, with stable profits.
Score History
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash Risk not measured
How Well MEQIRI WarnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation Signal
Fairly valuedClosing price of 19 Nov 2026, used by the daily score.
In our model the price counts as cheap below $6.04 and expensive above $14.08 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $4.05 (cash-flow model) and $12.85 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $8.15, at 6.3% it would be $8.89.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (30.3).
Calculate with your own assumptionsCompany Performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 8.1% on the twelve months before. Revenue has grown solidly since 2006, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 72%, operating 29%, net 26%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 22 Mar 2027in 122 days
- Last reported
- 23 Oct 2026EPS reported $0.11 (expected $0.11)below expectations
Analyst Estimates
Earnings estimates have barely changed since 19 Nov 2026.
- Earnings per share
- $0.440.0%
- Revenue
- $1.08B0.0%
- Earnings per share
- $0.490.0%
- Revenue
- $1.17B0.0%
MEQIRI has stored the estimates since 19 Nov 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What Happened at Dong-E-E-Jiao
The key events of the last six months from our own data. A click takes you to the matching card.
Sector Comparison
686 rated companies in Healthcare
- This company
- 81
- Sector median
- 53
Categories Against the Sector Median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
ETFs That Hold Dong-E-E-Jiao
Held by 5 of the 100 largest US ETFs. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Vanguard FTSE Emerging Markets ETFVWO | 0.00% | 0.06% | $117.5B |
| Vanguard International High Dividend Yield ETFVYMI | 0.00% | 0.07% | $21.7B |
| Vanguard FTSE All-World ex-US ETFVEU | 0.00% | 0.04% | $66.3B |
Show 2 more
| Vanguard Total International Stock ETFVXUS | 0.00% | 0.05% | $160.6B |
| Vanguard Total World Stock ETFVT | 0.00% | 0.06% | $82.8B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data Status and Sources
- Score
- Daily value of 20 Nov 2026, recalculated nightly
- Price
- Closing price of 20 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory Disclosures for This Rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 26 Sep 2025)
- Valuation signal Fairly valued since 18 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
